INTERMITTENT ANDROGEN DEPRIVATION THERAPY IN THE ERA OF ANDROGEN RECEPTOR PATHWAY INHIBITORS; A PHASE 3 PRAGMATIC RANDOMISED TRIAL

Informations projet

DE-ESCALATE

N° de convention de subvention: 101104574

DOI

10.3030/101104574

Date de signature de la CE 21 Avril 2023

Date de début 1 Juin 2023

Date de fin 31 Mai 2028

Financé au titre de

• Health

Coût total

€ 7 185 663,75

Contribution de l’UE

€ 7 185 663,00

Coordonné par

EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL
Belgium

CORDIS fournit des liens vers les livrables publics et les publications des projets HORIZON.

Les liens vers les livrables et les publications des projets du 7e PC, ainsi que les liens vers certains types de résultats spécifiques tels que les jeux de données et les logiciels, sont récupérés dynamiquement sur OpenAIRE .

Livrables

Documents, reports (5)

Plan for dissemination and exploitation

The plan that will describe project strategy for communication and dissemination

Conclusions of common annual meeting of the ‘Diagnosis and treatment’ cluster 1

Conclusions of common annual meeting of the ‘Diagnosis and treatment’ cluster

Policy brief 1

Policy brief formulating recommendations based on the research and innovation strand of the ‘Diagnosis and treatment’ annual cluster meeting

Data Management Plan

The DMP will describe which data/variables are collected, the standards used, how they are processed and stored and how they could be accessed.The preparation of the Data Management Plan will include a common chapter on the ‘Diagnosis and treatment’ cluster. The aim is of the chapter is to address commonalities in data standards, data validation, data protection and foster data exchange.

Initial common work plan for scientific collaboration under the ‘Diagnosis and treatment’ cluster

Other (1)

Project website is online

launch of the project dedicated public website

Publications

Peer reviewed articles (1)

"EORTC 2238 ""De-Escalate"": a pragmatic trial to revisit intermittent androgen deprivation therapy in the era of new androgen receptor pathway inhibitors."

Auteurs: Grisay G, Turco F, Litiere S, Fournier B, Patrikidou A, Gallardo E, McDermott R, Alanya A, Gillessen S, Tombal B
Publié dans: Frontiers in oncology, 2024, ISSN 1664-3224
Éditeur: Frontiers media
DOI: 10.3389/FONC.2024.1391825

Conference proceedings (1)

EORTC GUCG 2238 De-escalate: A pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-naïve prostate cancer in the era of new AR pathway inhibitors.

Auteurs: Guillaume Grisay, Fabio Turco, Anna Patrikidou, Enrique Gallardo Díaz, Raymond S. McDermott, Saskia Litiere, Beatrice Fournier, Silke Gillessen, and Bertrand F. Tombal
Publié dans: Journal of Clinical Oncology, 2024, ISSN 0732-183X
Éditeur: American Society of Clinical Oncology
DOI: 10.1200/JCO.2024.42.4_suppl.TPS2